> News and events
> UK’s NICE supports the use of QuikRead go for CRP testing in primary care
UK’s NICE supports the use of QuikRead go for CRP testing in primary care
As the flu season is approaching, it is good to remember the importance of CRP testing in primary care. For QuikRead go CRP, UK’s NICE formed Medtech Innovation Briefing. The key points from the evidence summarised in this briefing are from two randomised controlled trials, which reported reduced antibiotic prescribing rates compared with standard care. Briefing also reported that QuikRead go CRP testing technology performed with a similar accuracy as a standard laboratory CRP test in detecting pneumonia.
MIBs provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.
Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals.
Read the full briefing: https://www.nice.org.uk/advice/mib78
QuikRead go® CRP
Test before prescribing
QuikRead go CRP is a fast and simple rapid test for quantitative determination of C-reactive protein (CRP) in whole blood, serum and plasma with the QuikRead go instrument. The test gives reliable results within minutes and speeds up the path to the right diagnosis. Accurate measurement of C-reactive protein (CRP) can be critical in the clinical management of a patient with symptoms of infection. Read more: QuikRead go CRP and QuikRead go CRP+Hb